<DOC>
	<DOCNO>NCT00006026</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness nitrocamptothecin treat patient metastatic cancer urinary tract .</brief_summary>
	<brief_title>Nitrocamptothecin Treating Patients With Metastatic Cancer Urinary Tract</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response nitrocamptothecin patient metastatic urothelial tract tumor . II . Determine response rate patient treat regimen . III . Determine duration objective response patient treat regimen . IV . Characterize toxicity treatment patient population . OUTLINE : This multicenter study . Patients receive oral nitrocamptothecin daily day 1-5 . Treatment continue weekly every 3 week least 2 course absence disease progression unacceptable toxicity . Patients follow every 6 week disease progression . PROJECTED ACCRUAL : A total 14-25 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic unresectable primary carcinoma urinary tract include bladder , ureter , renal pelvis Transitional cell carcinoma OR Mixed cell carcinoma OR Squamous cell carcinoma OR Adenocarcinoma Measurable disease At least 20 mm conventional technique OR At least 10 mm spiral CT scan No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase transaminases great 2.5 time ULN ( great 5 time ULN case hepatic metastasis ) Renal : Creatinine great 1.7 mg/dL Cardiovascular : Normal cardiac function No ischemic disease past 6 month Other : Not pregnant nursing Fertile patient must use effective contraception No prior malignancy except cone biopsied carcinoma cervix adequately treat basal squamous cell skin carcinoma No concurrent unstable systemic disease active uncontrolled infection No psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Must receive 1 prior chemotherapy regimen advance metastatic disease At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 14 day since prior major surgery Other : No concurrent anticancer agents No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>squamous cell carcinoma bladder</keyword>
	<keyword>adenocarcinoma bladder</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
</DOC>